New technologies are poised to shake up life sciences and transform key points in the value chain.
Although the rise of new technologies over the past 20 years has led to tremendous disruption and new competition in most industries, life sciences have proven more stable with enduring barriers to entry for start-up players. Now, disruption is on its way.
Two key technologies have become increasingly cost efficient and sophisticated: The cost of genomic sequencing has fallen enormously to a fraction of what it was a decade ago, and low-cost individual genome editing appears ever more imminent thanks to the rise of CRISPR technology. Together, these technologies promise to enable personalized therapies across mass populations, ushering in a new era for biotech and pharmaceutical companies. While the full ramifications will only reveal themselves in time, disruptions of the past provide a precedent for what to expect.
In this whitepaper, we outline how emerging technologies are likely to disrupt the life sciences industry—and how today’s leading firms can prepare to defend their competitive advantage.